<DOC>
	<DOCNO>NCT01251718</DOCNO>
	<brief_summary>To investigate clinical safety effectiveness donepezil hydrochloride administration patient mild moderate Alzheimer 's Disease</brief_summary>
	<brief_title>Post-marketing Surveillance Donepezil Hydrochloride -Investigation Clinical Safety Effectiveness Patients With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Inclusion criterion ; Patients diagnose Alzheimer 's Disease Diagnostic Statistical Manual Mental Disorders ( DSMIV ) . Patients diagnose mild moderate Alzheimer 's Disease , applicable Functional Assessment Staging ( FAST ) score 4 5 . Exclusion criterion ; Patients use Aricept within 3 month prior dose . Patients register survey . Patients history hypersensitivity ingredient Aricept piperidine derivative .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Donepezil hydrochloride</keyword>
	<keyword>Alzheimer 's Disease</keyword>
</DOC>